Capacity planning for new molecules in biotech is fraught with uncertainty. Supply constraints, unknown titers, number of patients and dosing as well as probability of technical success (PTS), make capacity planning difficult. And while building insufficient capacity may have significant negative revenue implications, building too much capacity ties up capital and increases fixed manufacturing costs. With capital costs contributing as much as 30% of the overall cost per kilogram, making the right decision about capacity investment is critical. 

In this webinar we'll outline a number of approaches to understanding and managing the uncertainty associated with capacity planning. We'll explore how to evaluate the capacity of existing and new biomanufacturing facilities at a range of titers and volume ranges. We'll also show how to plan for a portfolio of new indications, identifying potential outliers ('black swans') that must be specially accounted for.

Register using the link below (free, registration required):